Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 29, 2021 Expiration: March 28, 2022
Start Activity
Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma
Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD
Noopur Raje, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
  • Identify characteristics of patients who are candidates appropriate for treatment with CAR T-cell therapy
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia or B-cell lymphomas
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma or CLL
  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools

Information on this Educational Activity

Program Director

Renier J. Brentjens, MD, PhD

Associate Professor
Department of Medicine
Weill Medical College of Cornell University
Associate Professor
Department of Pharmacology
Weill Cornell Graduate School of Medical Sciences
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Renier J. Brentjens, MD, PhD, has disclosed that he has patents and receives grant support from Juno Therapeutics (a Bristol-Myers Squibb company) and is a consultant/advisor for Gracell Therapeutics.

Faculty

Frederick L. Locke, MD

Co-Leader, Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director
Medical Director

Immune Cell Therapy Program
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida

Frederick L. Locke, MD, has disclosed that he has received consulting fees from Cellular Biomedicine, has received funds for research support from Gilead Sciences/Kite, and has served on advisory boards for Allogene, Amgen, Calibr, Bristol-Myers Squibb, GammaDelta Therapeutics, Gilead Sciences/Kite, Novartis, and WuGen.
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received funds for research support from Bluebird and consulting fees from Amgen, Bristol-Myers Squibb, Caribou, Immuneel, Janssen, Karyopharm, and Takeda.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Bronwen Shaw, MD
CME Content Reviewer
Bronwen Shaw, MD, has no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians and other healthcare professionals who treat and manage patients with B-cell lymphomas, CLL, or multiple myeloma who are candidates for CAR T-cell therapies.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Continuing Medical and Professional Education

ACCME Accreditation Statement
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

AMA Credit Designation
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hour participation for continuing education for allied health professionals.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 29, 2021, through March 28, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies
  • CME

Loading...
In this interactive on-demand Webcast, expert faculty members discuss how they currently use CAR T-cells to treat hematologic malignancies and provide a look ahead at new data and promising agents that may soon change practice.
Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD
Noopur Raje, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 29, 2021 Expiration: March 28, 2022

Related Content

Commentary on considerations affecting therapy recommendations for patients with myeloma in the evolving treatment landscape, from Clinical Care Options (CCO)

Brian G.M. Durie, MD
Program Director
Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD
Released: December 7, 2021

Commentary from Dr. Julie Vose on how to select therapy for patients with EBV-positive PTLD, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 6, 2021

Downloadable PDF resource guide with key information and resources for optimal management of patients with T-cell lymphomas, from clinical care options (CCO)

Talha Khan, PharmD, BCOP Released: December 6, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 6, 2021
Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue